Immatics (IMTX) Net Income (2019 - 2025)
Immatics (IMTX) posted Net Income of -$41.6 million for Q4 2025, up 86.88% sequentially from -$316.8 million in Q3 2025, and down 195.42% YoY from $43.6 million in Q4 2024.
Immatics (IMTX) Net Income (2019 - 2025) Analysis & Trends
Immatics has reported Net Income for 7 years, with the latest figure at -$41.6 million in Q4 2025.
- Quarterly Net Income fell 195.42% year-over-year to -$41.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$230.4 million (down 1630.47% YoY) and the FY2025 annual result came in at -$221.9 million, down 1447.51% from the prior year.
- Net Income grew to -$41.6 million in Q4 2025 per IMTX's latest filing, from -$316.8 million in the prior quarter.
- Over five years, Net Income peaked at $169.9 million in Q2 2025 and troughed at -$316.8 million in Q3 2025.
- A 5-year average of -$13.9 million and a median of -$20.2 million in 2021 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2025: Net Income soared 663.89% in 2023, then sank 1622.77% in 2025.
- Over 5 years, Net Income stood at -$19.2 million in 2021, then advanced by 29.7% to -$13.5 million in 2022, then surged by 663.89% to $76.1 million in 2023, then sank by 42.79% to $43.6 million in 2024, then slumped by 195.42% to -$41.6 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$41.6 million, -$316.8 million, and $169.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | -41.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.55 Mn |
| Sep 30, 2025 | -316.76 Mn |
| Jun 30, 2025 | 169.86 Mn |
| Mar 31, 2025 | -41.92 Mn |
| Dec 31, 2024 | 43.55 Mn |
| Sep 30, 2024 | -50.27 Mn |
| Jun 30, 2024 | 24.20 Mn |
| Mar 31, 2024 | -2.43 Mn |
| Dec 31, 2023 | 76.12 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | -13.50 Mn |
| Sep 30, 2022 | -21.11 Mn |
| Jun 30, 2022 | -14.92 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -148.47 Mn |
| Jun 30, 2021 | 86.90 Mn |
| Mar 31, 2021 | -27.52 Mn |